PinnyPeptide

Dihexa vs DNSP-11

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

Dihexa

Cognitive

Hepatocyte growth factor mimetic — claimed to be 7 orders of magnitude more potent than BDNF.

Peptide B

DNSP-11

Cognitive

Eleven-amino-acid peptide derived from the GDNF prodomain — neuroprotective for dopamine neurons.

Typical vial

30 mg

Typical dose

8,000-45,000 (oral) mcg

Half-life

~3-4 hours (oral)

FDA status

Not FDA approved. The related HGF-positive modulator fosgoni…

Typical vial

5 mg

Typical dose

Variable (research-specific) mcg

Half-life

Short; precise value uncharacterized

FDA status

Not FDA approved.

Dihexa effects

  • Claimed promotion of dendritic spine formation
  • HGF / c-Met signaling enhancement
  • Procognitive effects in rodent models
  • Orally bioavailable (rare for peptides)
  • Anecdotal cognitive enhancement in human users

DNSP-11 effects

  • Dopaminergic neuroprotection in Parkinson's models
  • Increased dopamine production in dopaminergic neurons
  • Improved motor function in 6-OHDA and MPTP models
  • Mechanism distinct from full-length GDNF
  • Investigational for Parkinson's and related disorders

Dihexa side effects

  • Essentially uncharacterized in humans
  • Headache (commonly reported in self-experimentation)
  • Increased emotionality / mood changes (subjective reports)
  • Theoretical: pro-oncogenic concerns via HGF / c-Met activation
  • Insomnia with late-day dosing

DNSP-11 side effects

  • Essentially uncharacterized in humans
  • Possible local tissue effects with intracerebroventricular delivery
  • Theoretical: off-target effects on non-dopaminergic neurons
  • Injection-site reactions

Dihexa dosing ranges

Cognitive research (oral / sublingual)

8-45 mg · Once daily · 30 days per cycle

DNSP-11 dosing ranges

Research / Parkinson's models (preclinical)

Variable per protocol · ICV or peripheral routes · Per research design

Full Dihexa guide → Full DNSP-11 guide →

Dihexa vs DNSP-11 — common questions

What is the difference between Dihexa and DNSP-11?

Dihexa: Hepatocyte growth factor mimetic — claimed to be 7 orders of magnitude more potent than BDNF. Typical dose 8,000-45,000 (oral) mcg. DNSP-11: Eleven-amino-acid peptide derived from the GDNF prodomain — neuroprotective for dopamine neurons. Typical dose Variable (research-specific) mcg. Both fall under the Cognitive category.

Can you stack Dihexa and DNSP-11?

Stacking Dihexa with DNSP-11 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, Dihexa or DNSP-11?

Dihexa is typically dosed: Once daily for Cognitive research (oral / sublingual). DNSP-11 is typically dosed: ICV or peripheral routes for Research / Parkinson's models (preclinical).

Are Dihexa and DNSP-11 FDA approved?

Dihexa: Not FDA approved. The related HGF-positive modulator fosgonimeton (ATH-1017) is in clinical trials for Alzheimer's. DNSP-11: Not FDA approved.

Related peptide comparisons

adamax vs dihexacolivelin vs dihexadihexa vs p21dihexa vs pe22-28dihexa vs pinealonadamax vs dnsp-11

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free